Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb;104(2):79-87.
doi: 10.1111/ejh.13348. Epub 2019 Dec 16.

The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients

Affiliations
Review

The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients

Johnny Cai et al. Eur J Haematol. 2020 Feb.

Abstract

Clinically significant bleeding can occur as a consequence of surgery, trauma, obstetric complications, anticoagulation, and a wide variety of disorders of hemostasis. As the causes of bleeding are diverse and not always immediately apparent, the availability of a safe, effective, and non-specific hemostatic agent is vital in a wide range of clinical settings, with antifibrinolytic agents often utilized for this purpose. Tranexamic acid (TXA) is one of the most commonly used and widely researched antifibrinolytic agents; its role in postpartum hemorrhage, menorrhagia, trauma-associated hemorrhage, and surgical bleeding has been well defined. However, the utility of TXA goes beyond these common indications, with accumulating data suggesting its ability to reduce bleeding and improve clinical outcomes in the face of many different hemostatic challenges, without a clear increase in thrombotic risk. Herein, we review the literature and provide practical suggestions for clinical use of TXA across a broad spectrum of bleeding disorders.

Keywords: antifibrinolytic agents; coagulants; fibrin modulating agents; heavy menstrual bleeding; hematologic agents; hematologic disorders; hemophilia; hemorrhage; hemostatic; postpartum hemorrhage; tranexamic acid; trauma.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Hunt BJ. The current place of tranexamic acid in the management of bleeding. Anaesthesia. 2015;70(Suppl 1) 50–53, e18. - PubMed
    1. Chornenki NLJ, Um KJ, Mendoza PA, et al. Risk of venous and arterial thrombosis in non-surgical patients receiving systemic tranexamic acid: A systematic review and meta-analysis. Thromb Res. 2019;179:81–86. - PubMed
    1. WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blinded, placebo-controlled trial. Lancet. 2017;389:2105–2116. - PMC - PubMed
    1. Ker K, Prieto-Merino D, Roberts I. Systematic review, meta-analysis and meta-regression of the effect of tranexamic acid on surgical blood loss. Br J Surg. 2013;100(10):1271–1279. - PubMed
    1. Roberts I, Shakur H, Coats T, et al. The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. Health Technol Assess. 2013;17(10):1–79. - PMC - PubMed

MeSH terms